We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Eisai Co., Ltd. has entered into a license agreement with medac Gesellschaft für klinische Spezialpräparate mbH (Medac) for the commercialization of its anti-rheumatic agent methotrexate (MTX) subcutaneous injection (pre-filled syringe) in Japan.